Reviewed by WANGYATAO·Last reviewed 2026-11-11·Medical disclaimer

In short

COPD patients are increasingly affected by pulmonary aspergillosis in several forms; timely imaging, mycology, and targeted antifungals improve outcomes.

What this guide covers: Why COPD · Forms · Recognizing · Treatment · Practical

Why COPD

Is Vulnerable People with COPD, especially severe disease, have weak airway defenses. Aspergillus can colonize, sensitize, or invade the lung. Steroids, broad antibiotics, diabetes, and critical illness raise the risk of invasive disease.

Forms

Of Disease COPD-related aspergillosis ranges from invasive pulmonary aspergillosis and subacute invasive forms to chronic pulmonary aspergillosis and ABPA-like allergy. These types can shift as immune status changes, so careful tracking is needed.

Recognizing

It Symptoms such as cough, sputum, and breathlessness often mimic COPD flares. Hemoptysis is suggestive. High-resolution CT and testing of sputum or lung fluid for Aspergillus, including galactomannan, support diagnosis.

Treatment

Approach Voriconazole, isavuconazole, or posaconazole are first-line for invasive disease; echinocandins or amphotericin B are alternatives. Chronic forms often use itraconazole or voriconazole for at least six months. Avoid unneeded steroids.

Practical

Notes Empirical antifungals are not advised for vague symptoms alone. In high-risk, failing cases, early treatment with parallel testing is reasonable. Stopping rules depend on imaging, cultures, and risk-factor control.

Sources and further reading

One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.

General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.